Mriglobal
Mriglobal, doing business as Midwest Research Institute, is a 501(c)(3) not-for-profit research organization based in Kansas City, Missouri, that provides comprehensive scientific research, testing, training, and product development services to federal and commercial clients. With over $110 million in annual research, the organization specializes in supporting critical national security, public health, and scientific innovation initiatives across various federal agencies. Mriglobal leverages its sophisticated laboratory facilities and technical expertise to develop medical countermeasures, conduct biosafety testing, perform infectious disease research, and support advanced scientific programs for government and commercial entities.
Through its federal contract awards, Mriglobal has provided a wide range of specialized scientific services across multiple domains. These include manufacturing clinical-grade vaccines for the National Cancer Institute, developing portable laboratory identification systems for the Environmental Protection Agency, creating curricula and training materials for the Department of Agriculture, conducting process development for tuberculosis treatments, and supporting chemical, biological, radiological, and nuclear defense research for the Joint Program Executive Office. The organization has worked extensively with agencies like the National Institutes of Health, Centers for Disease Control and Prevention, Department of Homeland Security, and Department of Defense, performing tasks such as drug substance development, analytical testing, pharmaceutical manufacturing, and threat detection technology evaluation. Most of these contracts were awarded without small business set-aside designations, indicating Mriglobal's capabilities as a large, experienced prime contractor.
Mriglobal's federal grant awards have focused on supporting scientific research and development across various domains. These grants have included community project funding for enhancing biorepository capabilities, expanding life sciences research infrastructure, and supporting specific scientific research initiatives. The organization has collaborated with academic institutions like the University of Colorado on research projects investigating medical treatments, such as developing therapies for ocular injuries caused by vesicating agents, studying post-translational histone modifications, and exploring antidotes for toxic gases. Grants have been awarded by agencies including the Department of Health and Human Services, with sub-awards to research institutions like Yale University and the University of Colorado, demonstrating Mriglobal's role in facilitating and supporting advanced scientific research.
Mriglobal holds numerous significant Indefinite Delivery Contracts (IDVs) across multiple federal agencies, providing flexible scientific research and development capabilities. These include a $146.3 million IDC with the National Institute of Allergy and Infectious Diseases for pre-clinical evaluation of infectious disease countermeasures, a $100 million contract with the Office of the Assistant Secretary for Preparedness and Response for biological animal model and medical countermeasure development, and a $49.7 million contract with the National Center for Advancing Translational Sciences for chemistry, manufacturing, and controls services. Other notable IDVs include a $2 billion COVID-19 testing solutions contract with the Department of Homeland Security, a $45 million contract for chemical threat animal model development, and multiple contracts with the National Cancer Institute for research and repository services. These IDVs allow federal agencies to rapidly procure Mriglobal's specialized scientific and technical services across critical research and development programs.
HKQHNFKNKL15 541715
Not listed 425 Dr Martin Luther King Jr Blvd, Kansas City, MO 64110, USA
7/24/01 12/15/26 Lovelace Biomedical Research Institute
Lovelace Biomedical Research Institute is a not-for-profit preclinical contract research organization located in Albuquerque, New Mexico, that provides comprehensive scientific research and development services to federal agencies. The organization specializes in delivering advanced preclinical research capabilities across various therapeutic areas, including animal studies, analytical testing, disease model development, inhalation toxicology, medical countermeasure testing, and product development. Registered in SAM.gov since 2003, Lovelace Biomedical Research Institute serves as a parent organization with extensive experience supporting federal research needs through contract and grant awards.
Through federal contract awards, Lovelace Biomedical Research Institute has performed diverse scientific services for multiple federal agencies. Notable contract work includes toxicological studies for the Food and Drug Administration's Center for Tobacco Products, pulmonary function testing for the National Heart, Lung, and Blood Institute, and respiratory interaction studies for the National Institute on Drug Abuse. The organization has executed contracts examining cigarette sensory effects, synthetic cooling agents, and potential treatments for respiratory depression. Most contracts were awarded without specific small business set-aside designations and involved multiple federal agencies such as NIH, FDA, and ASPR, with contract values ranging from a few thousand to several million dollars. Lovelace has worked as both a prime and sub-contractor, collaborating with entities like Research Triangle Institute and SRI International.
The organization's federal grant awards demonstrate a strong focus on advanced neuroscience, medical research, and innovative therapeutic investigations. Grants from agencies like the National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, and the National Science Foundation have supported projects ranging from music training interventions for children with Fetal Alcohol Spectrum Disorder to neuroimaging studies of traumatic brain injury. Other significant grant work includes research on cognitive sequelae in post-acute COVID-19 syndrome, mechanisms of cerebral microcirculation, and studies on incarcerated populations' mental health outcomes. These grants often involve collaborations with academic institutions like the University of New Mexico and involve sophisticated research methodologies including neuroimaging, behavioral assessments, and advanced statistical analyses.
Lovelace Biomedical Research Institute holds multiple significant federal contract Indefinite Delivery/Indefinite Quantity (IDIQ) contracts across various domains. These include a $136.6 million contract with the National Institute of Allergy and Infectious Diseases for evaluation and testing services for vaccines, a $48.8 million contract with the National Center for Advancing Translational Sciences for pharmacology studies and animal model development, and a $100 million contract with the Office of the Assistant Secretary for Preparedness and Response for biological animal model and medical countermeasure development. These IDVs cover a wide range of services including preclinical product development, safety evaluations, toxicology studies, and support for infectious disease research. Task orders have been issued by agencies like FDA, ASPR, and NIH, demonstrating the breadth and depth of Lovelace's capabilities in supporting complex federal research and development needs.
MBT9RXJJ7428 541714
Not listed 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
11/26/03 2/10/26 IIT Research Institute
IIT Research Institute (IITRI) is a non-profit contract research organization and subsidiary of the Illinois Institute of Technology, specializing in preclinical drug development services for federal agencies. Located in Chicago, Illinois, IITRI provides comprehensive research support across multiple scientific and technical domains, with a primary focus on delivering advanced research and development services to government agencies. The organization primarily serves federal agencies within the National Institutes of Health (NIH), including the National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, and National Institute of Allergy and Infectious Diseases.
Through federal contract awards, IITRI has consistently provided sophisticated preclinical research services, particularly in toxicology, pharmacology, and safety assessments for potential therapeutic candidates. The organization conducts extensive non-GLP and GLP toxicology studies involving rodents, dogs, and mice, supporting investigational new drug (IND) applications across various therapeutic areas including cancer, neurological disorders, and infectious diseases. IITRI's contract work encompasses detailed studies such as dose range finding, safety evaluations, efficacy assessments, and pharmacokinetic analyses. These contracts are typically awarded on a cost-plus-fixed-fee or firm-fixed-price basis, with no specific set-aside designations, and involve collaborations with prime contractors like Battelle Memorial Institute and Dynport Vaccine Company LLC.
Regarding grant awards, the available data shows limited information, with only one sub-grant award noted. This specific sub-grant award to the University of Massachusetts was for a research project titled "Energetic Variational Inference: Foundations, Algorithms, and Applications," indicating IITRI's potential involvement in advanced computational and mathematical research domains. However, the provided data does not provide comprehensive details about IITRI's grant activities.
IITRI holds several significant Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicles with substantial potential values. These include a $146.3 million contract with the National Institute of Allergy and Infectious Diseases for preclinical models of infectious diseases, a $48.6 million contract with the National Center for Advancing Translational Sciences for safety evaluation and toxicology studies, a $149.995 million PREVENT Cancer Preclinical Drug Development Program with the National Cancer Institute, and a $174.47 million Pharmacology and Toxicology for Therapeutics Program with the National Institute of Neurological Disorders and Stroke. These IDVs enable IITRI to provide specialized research services across various therapeutic areas, supporting critical drug development efforts from discovery through potential clinical trials.
DGBUFQYMKWB5 541715
Not listed 10 W 35th St #4, Chicago, IL 60616, USA
4/15/02 9/10/26 Sri International
Sri International, formerly known as Stanford Research Institute, is a non-profit research and development organization headquartered in Menlo Park, California. The organization provides advanced scientific, technical, and research services to various federal agencies through contracts and grants, spanning diverse domains such as defense technologies, biomedical sciences, computing, aerospace, environmental technologies, and national security. SRI International leverages its multidisciplinary expertise to develop innovative solutions for complex challenges, working across sectors including government, industry, and academia to advance technological capabilities and address critical research needs.
Through federal contract awards, Sri International has delivered a wide range of goods and services primarily to defense and civilian agencies. Notable contract work includes developing advanced sensor technologies, microcircuit components, and research program support services for agencies like the Defense Advanced Research Projects Agency (DARPA), National Institutes of Health (NIH), Air Force Research Laboratory, and Defense Logistics Agency. The organization has provided services such as electro-optical and infrared system development, digital microcircuit production, cybersecurity research, autonomous technologies research, and specialized engineering solutions. Most contract awards were not set aside for small businesses, reflecting SRI's status as a large, established research organization. The contracts often involve complex research and development efforts, with task orders ranging from developing artificial intelligence quantification technologies to creating advanced materials and exploring novel scientific methodologies.
In federal grant awards, Sri International has focused on research across educational, scientific, and social domains. Grant work includes developing STEM education programs, investigating collaborative programming models for K-12 computer science education, conducting geoscience research on atmospheric phenomena, and supporting health-related studies such as menopausal hot flash research and neurological investigations. Funding agencies have included the National Science Foundation, National Institutes of Health, Department of Justice, and Department of Energy. The grants often involve collaborative research with universities and other research institutions, addressing critical areas like trauma-sensitive school interventions, space weather observations, and emerging technologies in fields such as quantum information science and biotechnology.
Sri International holds multiple federal contract Indefinite Delivery Vehicles (IDVs) across various agencies, particularly with DARPA and NIH. These IDVs cover a broad spectrum of research and development services, including Other Transaction Agreements for advanced technologies like autonomous systems development, artificial intelligence research, sensor technologies, and specialized engineering solutions. The IDVs with DARPA focus on innovative research areas such as network deployment, velocity measurement technologies, and emerging computational methodologies. NIH-awarded IDVs concentrate on interventional agent development, safety evaluation, and toxicology studies. The IDVs provide flexible mechanisms for agencies to access SRI's specialized technical capabilities, with ceiling values ranging from approximately $500,000 to $50 million, enabling rapid procurement of cutting-edge research and development services across multiple scientific and engineering domains.
SRG2J1WS9X63 541715
Not listed SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA
5/21/01 5/28/26 Charles River Laboratories, Inc.
Charles River Laboratories, Inc., headquartered in Wilmington, Massachusetts, is a global contract research organization that provides essential products and services to support pharmaceutical, biotechnology, and government research and development efforts. The company specializes in laboratory animal procurement and maintenance, preclinical and clinical laboratory services, diagnostic testing, vaccine development support, toxicology studies, and related biomedical research capabilities. Charles River has established itself as a critical partner for federal agencies by delivering specialized research models, cellular products, and scientific services that enable government-sponsored research across multiple scientific domains and therapeutic areas.
Through its prime federal contract awards, Charles River has demonstrated extensive capabilities in providing laboratory animals across multiple species and strains, including mice, rats, guinea pigs, rabbits, and hamsters, along with associated breeding colonies, health surveillance services, and cryopreservation of genetic materials. The company has provided rederivation services for mouse colonies, cryopreservation and storage of sperm and embryos, rodent health testing and surveillance services, and diagnostic testing for laboratory animals. Charles River has also performed specialized services including the development and maintenance of multigenotypic aged mouse and rat colonies for the National Institute on Aging—contracts valued in the millions of dollars—as well as vaccine candidate preparation and characterization, influenza and coronavirus challenge virus production, universal vaccine development, and clinical trial material manufacturing. The company has operated the Alamogordo Primate Facility on behalf of the National Institutes of Health and the U.S. Air Force, managing care for chimpanzees over an eight-million-dollar contract. Additionally, Charles River has provided aquatic care services, animal laboratory testing services, toxicology and pharmacology studies, immunohistochemistry staining services, and cell bank production. Federal funding agencies awarding prime contracts to Charles River include the National Institutes of Health and its constituent institutes (National Institute on Aging, National Institute of Allergy and Infectious Diseases, National Heart Lung and Blood Institute, National Institute of Environmental Health Sciences, and others), the Department of Veterans Affairs through multiple Veterans Integrated Service Networks, the Food and Drug Administration, the Defense Health Agency, the Department of Defense components, the Centers for Disease Control and Prevention, and the Department of Agriculture. None of Charles River's prime contract awards have utilized small business or other socioeconomic set-aside designations, reflecting the company's competitive standing in federal procurement. As a subcontractor, Charles River has provided laboratory animals and related services to prime contractors including Battelle Memorial Institute, Sri International, Research Triangle Institute, Colorado State University, Amentum Services, Inc., and Takeda Vaccines Inc.
Charles River holds multiple significant indefinite delivery contracts with federal agencies that establish long-term relationships for specialized research support. The company maintains a $65.1 million, ten-year IDC with the National Institute on Aging for the development and maintenance of a multigenotypic aged mouse colony, with annual task orders ranging from approximately $736,000 to $7.3 million. Similarly, Charles River holds a $29.8 million, ten-year IDC with the National Institute on Aging for aged rat colony development and maintenance. The company also maintains a $48.6 million IDC with the National Center for Advancing Translational Sciences for safety evaluation and toxicology studies and related services for drug development, supporting in vitro and in vivo studies on small molecules and biologics. The National Institute of Environmental Health Sciences has awarded Charles River a $1.5 million IDC for barrier-reared and maintained rodents and specialized animal services, and a $1.83 million IDC for laboratory animal diagnostic testing services. Additional IDCs include a $1.13 million contract with the Department of the Navy Bureau of Medicine and Surgery for F344 rats, a $6.16 million IDC with the Naval Supply Systems Command for various rodent strains and rabbits, a $2.44 million IDC with the Department of Agriculture for fertilized specific pathogen-free chicken eggs, and a $250,000 IDC with the Department of Veterans Affairs Veterans Integrated Service Network 1 for rodent testing services. Charles River was recently awarded a $250,000 IDC by Veterans Integrated Service Network 20 for rodent health testing and monitoring services, and maintains a $35 million Blanket Purchase Agreement with the Defense Health Agency for small laboratory research animals. The company also holds a $750,000 Federal Supply Schedule contract through the General Services Administration's Multiple Award Schedule vehicle, which has generated delivery orders from the Food and Drug Administration and Department of Veterans Affairs for laboratory animal supplies. These IDCs reflect the depth of Charles River's relationships with federal agencies and the critical nature of the specialized research support services the company provides to advance government-sponsored biomedical research initiatives.
NAPSK1UAMAE5 112990
Not listed 251 Ballardvale St, Wilmington, MA 01887, USA
4/23/02 7/1/26